Figure 6. Prolonged treatment of H1666 cells with Dabrafenib, AZ628, and Trametinib alone or in combination.

H1666 cells were incubated for seven days with Dabrafenib (2.5 μM), AZ628 (2.5 μM), or Trametinib (25 nM) alone or in combination (Dabrafenib or AZ628 plus Trametinib). Viability was measured, and relative viability was determined via normalization to the vehicle group (A). Means ± SEM are from four independent experiments, each performed in four replicates. Alternatively, cells treated as described were incubated and monitored in an Incucyte device and confluency was determined at several time points (B). Images representative of different conditions in (B) were taken after seven days (C). ^*p ≤ 0.05, ^**p ≤ 0.01, ^***p ≤ 0.001.